Education
About Us
Working with TipRanks
Follow Us
Purple Biotech Ltd. (PPBT)
:PPBT
Top Page
Purple Biotech
(NASDAQ:PPBT)
47Neutral
Positive Factors
Biomarker Analysis
Various biomarker analysis on the Phase 2 CM24 trial demonstrates improved overall survival.
Efficacy of CM24
The CM24 experimental arm had consistently greater efficacy for every evaluated endpoint.
Negative Factors
Imbalance in Clinical Trial
The CM24 + nivolumab + gem/nab-paclitaxel cohort was impacted by informative censoring of the control arm which led to an imbalance in the number of patients in the active and control arms.
Purple Biotech (PPBT) vs. S&P 500 (SPY)
Market Cap
$7.28M
Dividend YieldN/A
Average Volume (3M)18.50K
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue GrowthN/A
EPS Growth56.99%
CountryUS
Employees20
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.94
Shares Outstanding2,648,200
10 Day Avg. Volume15,060
30 Day Avg. Volume18,498
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$33.00Price Target Upside1108.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Purple Biotech Business Overview & Revenue Model
Company DescriptionPurple Biotech (PPBT) is a clinical-stage company specializing in the development of innovative oncology therapies. Based in Israel, the company is committed to advancing its pipeline of therapeutics aimed at addressing unmet medical needs in cancer treatment. Purple Biotech's core products include investigational drug candidates that target multiple cancer pathways to improve patient outcomes.
How the Company Makes MoneyPurple Biotech generates revenue primarily through strategic partnerships, licensing agreements, and research collaborations with other pharmaceutical and biotechnology companies. These collaborations often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of its drug candidates. Additionally, the company may receive government grants or funding from non-profit organizations to support its research and development activities.
Purple Biotech Financial Statement Overview
Summary
Purple Biotech faces significant financial challenges with negative revenue and net income, indicating ongoing losses. Despite a stable equity position, the company struggles with operational inefficiencies and negative cash flows, necessitating strategic changes for financial improvement.Income Statement
Purple Biotech's income statement reflects significant challenges with profitability and revenue generation. The company has not achieved positive total revenue in recent periods, showing a consistent decline. Net income is negative, indicating ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and challenges in cost management.20
Very Negative
Balance Sheet
The balance sheet shows a moderately stable capital structure with a low debt-to-equity ratio, indicating minimal reliance on debt financing. The equity ratio is strong, suggesting that the company has a high proportion of equity financing compared to total assets. However, declining stockholders' equity over time raises concerns about the sustainability of this structure.55
Neutral
Cash Flow
Cash flow analysis reveals negative operating and free cash flows, indicating that the company is not generating sufficient cash from its core operations. The free cash flow growth rate is negative, reflecting a deterioration in cash flow generation capability. The operating cash flow to net income ratio is less relevant given consistent negative net income values.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | -910.00K | -320.00K | 1.00M | 1.00M | Gross Profit |
| -145.00K | -196.00K | -1.11M | -551.00K | 765.00K | 999.92K | EBIT |
| -16.32M | 22.27M | -22.60M | -17.93M | 12.61M | -7.16M | EBITDA |
| -11.14M | -22.23M | -21.49M | -17.52M | -28.41M | -6.14M | Net Income Common Stockholders |
| -11.66M | -19.88M | -20.82M | -18.46M | -12.40M | -6.11M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 15.41M | 15.41M | 32.11M | 47.20M | 57.80M | 6.39M | Total Assets |
| 44.30M | 44.30M | 54.62M | 70.20M | 83.80M | 14.72M | Total Debt |
| 351.00K | 351.00K | 515.00K | 749.00K | 895.00K | 223.00K | Net Debt |
| -14.14M | -14.14M | -14.52M | -10.14M | -10.35M | -4.16M | Total Liabilities |
| 10.01M | 10.01M | 7.52M | 5.09M | 4.05M | 3.86M | Stockholders Equity |
| 34.21M | 34.21M | 46.91M | 64.83M | 79.39M | 10.42M |
| Cash Flow | Free Cash Flow | ||||
| -17.08M | -19.23M | -16.96M | -15.19M | -12.25M | -5.59M | Operating Cash Flow |
| -17.08M | -19.23M | -16.73M | -15.07M | -12.09M | -5.58M | Investing Cash Flow |
| 346.00K | 13.88M | 19.91M | 13.41M | -49.59M | -449.00K | Financing Cash Flow |
| 7.11M | 5.45M | 1.11M | 1.51M | 68.49M | 5.23M |
Purple Biotech Technical Analysis
Negative
2.73
Price Trends
3.42
Negative
3.52
Negative
2.50
Positive
Market Momentum
-0.17
Positive
36.15
Neutral
23.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PPBT, the sentiment is Negative. The current price of 2.73 is below the 20-day moving average (MA) of 2.99, below the 50-day MA of 3.42, and above the 200-day MA of 2.50, indicating a neutral trend. The MACD of -0.17 indicates Positive momentum. The RSI at 36.15 is Neutral, neither overbought nor oversold. The STOCH value of 23.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PPBT.
Purple Biotech Risk Analysis
Purple Biotech disclosed 71 risk factors in its most recent earnings report. Purple Biotech reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Purple Biotech Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $49.69M | 1.58 | -58.97% | ― | 36.45% | ― | |
50 Neutral | $253.13M | ― | -31.16% | ― | ― | 15.17% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
47 Neutral | $7.28M | ― | -34.28% | ― | ― | 56.99% | |
44 Neutral | $114.38M | ― | -53.54% | ― | 145.37% | 57.01% | |
43 Neutral | $14.41M | ― | -474.63% | ― | ― | 50.73% | |
42 Neutral | $13.81M | ― | -151.46% | ― | -95.23% | -325.89% |
* Healthcare Sector Average
Performance Comparison
PPBT
Purple Biotech
2.73
2.02
284.51%
IMMP
Immutep
1.70
-0.91
-34.87%
AFMD
Affimed
0.89
-3.90
-81.42%
ADAP
Adaptimmune Therapeutics
0.46
-1.13
-71.07%
CLRB
Cellectar Biosciences
0.32
-3.22
-90.96%
CTMX
CytomX Therapeutics
0.60
-1.50
-71.43%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.